Two new studies have provided fresh evidence that adding telaprevir to standard hep C treatments increases the cure rate for patients. Sixty-nine percent of patients taking a combination of telaprevir, pegylated interferon and ribavirin achieved sustained viral eradication, compared to 46 percent of patients taking standard therapies over 48 weeks. "This is a breakthrough in HCV therapy," said lead researcher Dr. Jean-Michel Pawlotsky. "For the very first time, almost 70 percent cure rates are reached." He adds that an approval could come in two years. Report